Home » Topics » BioWorld Science

BioWorld Science
RSS

Fibrinogen antagonists reported by Searle

Oct. 4, 1996

Boehringer Mannheim reports fibrinogen antagonists for thromboembolic conditions

Oct. 4, 1996

Joint venture formed for development of oral heparin

Oct. 4, 1996

Interim phase II results reported for Neutralase

Oct. 4, 1996

Further patent coverage for vascular disease therapy

Oct. 4, 1996

New bi-ventricular pacemaker enters clinical trials

Oct. 4, 1996

HemoCleanse evaluates sorbent-based system in sepsis

Oct. 4, 1996

T Cell Sciences receives grant to develop CETP vaccine

Oct. 4, 1996

Alexion authorized to begin second clinical trial with C5 inhibitor

Oct. 4, 1996

TMR as adjunct to bypass surgery

Oct. 4, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 15, 2026.
ASGCT 2026: Circular RNA, the new beast in gene and cell therapy
BioWorld
Circular RNA (circRNA) is not a new concept, but it is a novel strategy in the field of gene and cell therapy. While mRNA vaccines have revolutionized medicine,...
Advancing the 'best of both' – BMS, Hengrui enter $15.2B deal
BioWorld
In a deal potentially worth up to $15.2 billion, Jiangsu Hengrui Pharmaceuticals Co. Ltd. is joining efforts with Bristol Myers Squibb Co. to advance 13 early...
News in brief
BioWorld Asia
BioWorld Asia briefs for May 12, 2026
ASGCT 2026: Uncovering the mechanisms of AAV toxicity
BioWorld
Gene therapies rely on vectors to reach the target tissue where they act, such as adeno-associated viruses (AAVs) or lipid nanoparticles (LNPs), among other...